Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG oligodeoxynucleotide 1668
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Preclinical (murine): Intraperitoneal, Preclinical: Intravenous, Preclinical: Subcutaneous
01
Overview
CpG oligodeoxynucleotide 1668 is a **class B synthetic oligonucleotide containing unmethylated cytosine-guanine (CpG) motifs with phosphorothioate backbone** that acts as a Toll-like receptor 9 (TLR9) agonist, specifically stimulating murine TLR9[4][1]. This compound is a 20-mer DNA sequence (5’-tccatgacgttcctgatgct-3’) engineered for nuclease resistance[4]. ODN 1668 induces strong **immunostimulatory effects**, leading to enhanced Th1-mediated CTL activation, pro- and anti-inflammatory cytokine production (IL-1Ra, IL-1α, IL-1β, IL-6, TNFα, IL-10), and nitric oxide release from macrophages[2][1]. Its primary biomedical use is as an experimental **immunomodulatory adjuvant** in preclinical models of cancer immunotherapy, especially murine models, where it enhances anti-tumor immunity, mainly via Th1 responses and CTL activation[1]. Unlike class A CpG ODNs, ODN 1668 does not directly activate NK cells but is a potent Th1 activator[1].
- Brand names
- ODN 1668ODN1668ODN-1668
- Other names
- ODN1668ODN-1668ODN 1668CpG-B ODN1668type B CpG oligodeoxynucleotide 1668
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on CpG oligodeoxynucleotide 1668.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG oligodeoxynucleotide 1668.